home · filing · 0001367644-24-000006
8-K filed February 21, 2024, 6:59 PM ET
ticker EBS
CIK 0001367644
leadership
confidence high
sentiment positive
materiality 0.75
Emergent BioSolutions appoints Joseph C. Papa as President and CEO, replacing interim CEO Haywood Miller
Emergent BioSolutions Inc.
Joseph C. Papa appointed President and CEO effective Feb 21, 2024; succeeds interim CEO Haywood Miller.
Papa brings over 35 years pharma experience, most recently CEO of Bausch + Lomb (NYSE: BLCO).
Compensation: $1M base salary, 130% bonus target, $1M sign-on bonus, 1.5M stock options, $8M performance incentive tied to share price.
Also appointed Class II director with term through 2026 annual meeting.
Press release emphasizes focus on strengthening balance sheet, returning to growth, and paying down debt.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2024-02-21
Successor Haywood Miller
Filed February 21, 2024, 6:59 PM ET
appointed Joseph C. Papa as President and CEO of the Company, effective February 21, 2024.
Effective 2024-02-21
Filed February 21, 2024, 6:59 PM ET
Mr. Papa has been appointed as Class II director of the Board
Effective 2024-02-21
Successor Joseph C. Papa
Filed February 21, 2024, 6:59 PM ET
Haywood Miller, who will step down from his role as interim CEO of the Company, effective February 21, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joseph C. Papa was appointed as President and CEO at Emergent BioSolutions Inc..
Action appointed
Role President and CEO
Exact text from the filing
appointed Joseph C. Papa as President and CEO of the Company, effective February 21, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joseph C. Papa was appointed as Class II director at Emergent BioSolutions Inc..
Action appointed
Role Class II director
Exact text from the filing
Mr. Papa has been appointed as Class II director of the Board
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Haywood Miller departed as Interim CEO at Emergent BioSolutions Inc..
Action stepped down
Role Interim CEO
Exact text from the filing
Haywood Miller, who will step down from his role as interim CEO of the Company, effective February 21, 2024.
View on SEC.gov
Source: SEC EDGAR
accession 0001367644-24-000006
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.